{
    "clinical_study": {
        "@rank": "70435", 
        "arm_group": [
            {
                "arm_group_label": "Part A - 14C labeled ARN-509", 
                "arm_group_type": "Active Comparator", 
                "description": "Single oral dose of 240 mg ARN-509, followed after 2 hours (at the average tmax of ARN-509) by an intravenous (i.v.) microdose of 100 \u03bcg (9.25 kBq, 250 nCi) 14C-ARN-509"
            }, 
            {
                "arm_group_label": "Part B: 14C labeled ARN-509", 
                "arm_group_type": "Active Comparator", 
                "description": "Single oral dose of 240 mg ARN-509, followed after 2 hours (at the average tmax of ARN-509) by an oral dose of 240 mg ARN-509 with 37 kBq (1000 nCi) of 14C-ARN-509"
            }
        ], 
        "brief_summary": {
            "textblock": "This is study in healthy human volunteers to determine the absorption, metabolism, and\n      excretion (AME) profile of ARN-509 as well as its absolute oral bioavailability (BA)."
        }, 
        "brief_title": "14C-ARN-509 Microtracer Label AME and Absolute BA Study", 
        "completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "detailed_description": {
            "textblock": "Two cohorts of 6 healthy volunteers will be enrolled for the AME and absolute BA parts,\n      respectively. The dose for both cohorts is 240 mg. The expected exposure of the dose is\n      7-fold lower than the steady state reached in patients with castration-resistant prostate\n      cancer."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Key Inclusion Criteria:\n\n          1. Gender : male\n\n          2. Age : 50 - 80 years, inclusive\n\n          3. Body Mass Index (BMI) : 18.5-30.0 kg/m2\n\n          4. Ability and willingness to abstain from alcohol, methylxanthine-containing beverages\n             or food (coffee, tea, cola, chocolate, \"power drinks\"), grapefruit (juice) and\n             tobacco products from 48 h prior to entry in the clinical research center until\n             discharge\n\n          5. Medical history without major pathology\n\n        Key Exclusion Criteria:\n\n          1. Evidence of clinically relevant pathology.\n\n          2. Mental handicap.\n\n          3. History of relevant drug and/or food allergies.\n\n          4. Regular/routine treatment with non-topical medications within 30 days prior to entry\n             into the clinical research center.\n\n          5. Smoking.\n\n          6. History of alcohol abuse or drug addiction (including soft drugs like cannabis\n             products).\n\n          7. Use of concomitant medication, except for acetaminophen (paracetamol) and topical\n             medications\n\n          8. Irregular defecation pattern (less than once per 2 days).\n\n          9. Positive drug screen (opiates, methadone, cocaine, amphetamines, cannabinoids,\n             barbiturates, benzodiazepines, and alcohol).\n\n         10. Intake of more than 24 units of alcohol per week (one unit of alcohol equals\n             approximately 250 mL of beer, 100 mL of wine or 35 mL of spirits).\n\n         11. Positive screen on HBsAg, anti-HCV or anti-HIV 1/2.\n\n         12. Illness within five days prior to drug administration."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "80 Years", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01822041", 
            "org_study_id": "ARN-509-006", 
            "secondary_id": "2012-004899-19"
        }, 
        "intervention": {
            "arm_group_label": [
                "Part A - 14C labeled ARN-509", 
                "Part B: 14C labeled ARN-509"
            ], 
            "description": "Single oral dose of 240 mg ARN-509", 
            "intervention_name": "ARN-509", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "healthy volunteers", 
            "mass balance study", 
            "Pharmacokinetics"
        ], 
        "lastchanged_date": "September 12, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Groningen", 
                    "country": "Netherlands"
                }, 
                "name": "PRA - Clinical Research Unit, University Medical Centre Groningen"
            }
        }, 
        "location_countries": {
            "country": "Netherlands"
        }, 
        "number_of_arms": "2", 
        "official_title": "14C-ARN-509 Microdose Absolute Bioavailability and Microtracer Absorption, Metabolism, and Excretion Study in Healthy Volunteers", 
        "overall_official": [
            {
                "affiliation": "PRA International Group BV", 
                "last_name": "Nada al Kotbi, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "PRA International Group BV", 
                "last_name": "Helen Pruim-Tait, MA, MSc", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "To determine the rate and routes of excretion of ARN-509 in urine, feces, and expired air", 
                "measure": "Mass Balance", 
                "safety_issue": "No", 
                "time_frame": "2 months 10 days"
            }, 
            {
                "description": "To determine absolute oral bioavailability of ARN-509", 
                "measure": "Absolute Oral Bioavailability", 
                "safety_issue": "No", 
                "time_frame": "2 months 10 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01822041"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "To identify and quantify the ARN-509 metabolites in plasma, urine, and feces", 
            "measure": "Metabolite Profile", 
            "safety_issue": "No", 
            "time_frame": "2 months 10 days"
        }, 
        "source": "Aragon Pharmaceuticals, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Aragon Pharmaceuticals, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}